SkinBioTherapeutics plc (LON:SBTX – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as GBX 19.06 ($0.24) and last traded at GBX 18.85 ($0.24), with a volume of 2420459 shares traded. The stock had previously closed at GBX 17.75 ($0.22).
SkinBioTherapeutics Stock Performance
The company has a market cap of £42.62 million, a price-to-earnings ratio of -887.50 and a beta of 2.01. The firm has a 50-day simple moving average of GBX 14.06 and a 200 day simple moving average of GBX 12.01. The company has a quick ratio of 10.01, a current ratio of 6.57 and a debt-to-equity ratio of 2.66.
About SkinBioTherapeutics
SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis.
Further Reading
- Five stocks we like better than SkinBioTherapeutics
- Why Are Stock Sectors Important to Successful Investing?
- Beyond NVIDIA: Top 5 Semiconductor Stocks to Watch for 2025
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Netflix Is On Track To Hit $1,000 By Christmas
- Why Invest in 5G? How to Invest in 5G Stocks
- UMAC Stock Climbs Amid Trump Jr. Appointment and Meme Stock Hype
Receive News & Ratings for SkinBioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SkinBioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
